Nicotinic acid/laropiprant: a new lipid‐modifying therapy

Cardiovascular disease (CVD) is a leading cause of death in the UK.¹ Blood choleserol levels are a key risk factor for CVD, and can be modified by both drug treatment and lifestyle changes. In this article, Steve Chaplin considers the available clinical data on a new lipid‐modifying therapy, a modified‐release formulation of nicotinic acid and laropiprant; and Marc Evans comments on its potential contribution to reducing the risk of CVD. Copyright © 2009 John Wiley & Sons, Ltd.